RESULTS	At week 12 , TDI focal scores were significantly greater with all arformoterol doses compared with placebo ( mean [ 95 % CI ] : 15 microg BID , 0.97 [ 0.25-1 .69 ] ; 25 microg BID , 1.08 [ 0.3-1 .86 ] ; 50 microg QD , 1.04 [ 0.32-1 .771 ) , suggesting treatment-associated improvement in dyspnea , however , the difference between salmeterol and placebo was not statistically significant ( 0.36 [ -0.40 to 1.12 ] ) .\